Important

Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following and confirm your country of residence. Your confirmation must be true and accurate.

By choosing a country below, you certify that you are an individual resident and located in the country selected by you above and that you have read and understood this notice.

Please confirm your location:

 

No access to the information

The information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Hong Kong, Canada, Japan, New Zealand, Singapore, or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

Important information

The information contained in this section of Endomines AB’s (publ) (“Endomines”) website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, or the United States or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any shares or other securities in Endomines in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or the United States or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

No subscription rights, paid subscription shares (Sw. betalda tecknade aktier) or new shares in Endomines (“Securities”) have been, or will, be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or the securities legislation of any state or other jurisdiction of the United States and thus the Securities may not be offered, subscribed for, exercised, pledged, sold, resold, granted, delivered or otherwise transferred, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities legislation in any state or other jurisdiction of the United States. The Securities have not been approved or disapproved by the U.S. Securities and Exchange Commission (SEC), any state regulatory authority in the United States or any other U.S. regulatory authority nor have any of the foregoing authorities passed upon or endorsed the merits of the offering or the accuracy or adequacy of the prospectus. Any representation to the contrary is a criminal offense in the United States.

Any offering of Securities will be made by means of a prospectus in accordance with Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with any related implementing and delegated regulations, the “Prospectus Regulation”). Investors should not invest in any Securities except on the basis of information contained in the aforementioned prospectus. In any EEA Member State other than Sweden, and in the United Kingdom (each, a “Relevant State”) this communication is only addressed to and is only directed at qualified investors in that Relevant State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such Relevant State.

Any investment or investment activity to which this information relates is available only to, and will be engaged in only with, persons who (i) are outside the United Kingdom, (ii) are investment professionals falling within Article 19(5) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the Order) or (iii) high net worth companies, and other persons to whom it may lawfully be engaged with, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as "relevant persons"). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on these documents or any of their contents.

Access to the information and documents contained on the following websites may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such information and documents. All persons residing outside of Sweden who wish to have access to the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside of Sweden. Endomines assumes no responsibility if there is a violation of applicable law and regulations by any person.

I therefore certify that:

  1. I am resident and physically present outside of Australia, Canada, Hong Kong, Japan, Singapore and the United States; and
  2. I am resident and physically present (a) in Sweden or (b) outside of Sweden and each of the jurisdictions referred to in clause (1) above and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by Endomines.
  3. I have read, understand and agree to comply with all of the restrictions set forth above.

Endomines rights issue 2021

Rights issue in brief

Endomines Board of Directors resolved on November 30, 2020 on a rights issue of shares to current shareholders (the “Rights Issue”). On January 4, 2021, the Extraordinary General Meeting approved the Board's decision.

The Rights Issue comprises a maximum of 112,547,292 new shares at a subscription price of SEK 2.50 per share in Sweden and 0.25 EUR per share in Finland, meaning that the Company will receive approximately MSEK 281 before transaction costs upon full subscription.

The person who, on the record date of January 7, 2021, is registered as a shareholder in Endomines, is entitled to subscribe for shares in the Rights Issue with pre-emptive rights and will receive one (1) subscription right for each held share. Seven (7) subscription rights entitles to subscription of six (6) new shares. Application for subscription of shares may also be made without subscription rights. The record date for participation in the Rights Issue is January 7, 2021 and the subscription period is January 11 – 25, 2021. Shareholders who choose not to participate in the Rights Issue will have their ownership diluted by up to approximately 46 percent, but are able to financially compensate for the dilution effect by selling their subscription rights.

Before you apply for subscription of shares, you should carefully read the prospectus that has been produced by Endomines in connection with the Rights Issue. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority as competent authority in accordance with the Prospectus Regulation (EU) 2017/1129. Such approval shall not be considered as an endorsement of Endomines or the quality of the shares that are offered. The prospectus is available below, as well as on www.aktieinvest.se/endomines2021, and will also be available in the prospectus register of the Swedish Financial Supervisory Authority, www.fi.se.

Timetable for the Rights Issue

January 7, 2021

The record date for participating in the Rights Issue, i.e. shareholders that are registered in the share register on this date will receive subscription rights that entitle them to participate in the Rights Issue

January 11, 2021

Subscription period begins

January 11, 2021

Trading in subscription rights begins on Nasdaq Stockholm and Nasdaq Helsinki

January 11, 2021

Trading in interim shares (”BTA”) begins on Nasdaq Stockholm

January 19, 2021

Trading in subscription rights ends on Nasdaq Stockholm and Nasdaq Helsinki

January 25, 2021

Subscription period ends

January 28, 2021

Trading in interim shares begins on Nasdaq Helsinki

On or about January 28, 2021

Announcement of the outcome of the Rights Issue

Prospectus

Prospectus (PDF, in Swedish)

Additional materials

Video presentation in English 11/01 2021

Video presentation in Finnish 11/01 2021

Info brochure (Instruction of subscription for shares in Sweden, in Swedish)

Info brochure (Instruction of subscription for shares in Sweden, in English)

Info brochure (Instruction of subscription for shares in Finland, in Finnish)

Subscription of shares in Sweden (”ENDO”)

Aktieinvest FK AB is the subscription place in Sweden. Instructions and subscription forms are available at Aktieinvest’s website: www.aktieinvest.se/endomines2021

Subscription of shares in Finland (”ENDOM”)

Each account operator, and nominee register holder in the case of nominee registered shares, in Finland provides instructions for subscription to their clients. Please follow the instructions from your account operator.

Releases

2020-11-30 – The Board of Endomines has resolved on a rights issue of MSEK 281

2021-01-04 – Resolutions from Extraordinary General Meeting of Endomines AB (publ) on 4 January 2021

2021-01-04 – Rights issue in Endomines AB (publ) – last day of trading in shares including subscription rights is 4 January 2021 on Nasdaq Stockholm and 5 January 2021 on Nasdaq Helsinki

2021-01-05 – Endomines invites to webcast company presentations 11 January 2021

2021-01-07 – Endomines publishes prospectus

Contact persons

Evli

Sweden:
Mikkel Johannesen
+46 73 147 0013, mikkel.johannesen@evli.com

Finland:
+358 9 4766 9573, (weekdays 9-16), operations@evli.com

Endomines

Marcus Ahlström, Interim CEO
+358 50 544 68 14, marcus.ahlstrom@endomines.com

Ingmar Haga, Chairman
+358 40 700 35 18, ingmar.haga@endomines.com